N-Methyl-3-phenoxybenzamid | 50789-46-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-Methyl-3-phenoxybenzamid
• 英文别名: n-Methyl-3-phenoxybenzamide
• CAS: 50789-46-3
• 化学式: C₁₄H₁₃NO₂
• 分子量: 227.263
• InChiKey: FKCUOISXAGPXMY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.7
• 重原子数：
  17
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.07
• 拓扑面积：
  38.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  3-苯氧基苯甲酰氯 、 甲胺 以 水 、 乙酸乙酯 为溶剂， 生成 N-Methyl-3-phenoxybenzamid
  参考文献：
  名称：

  DE2720427

  摘要：

  公开号：

文献信息

• [EN] PYRAZOLO-PYRIDINES AS TYROSINE KINASE INHIBITORS<br/>[FR] PYRAZOLO-PYRIDINES EN TANT QU'INHIBITEURS DE TYROSINE KINASE
  申请人：ARRAY BIOPHARMA INC

  公开号：WO2009033084A1

  公开（公告）日：2009-03-12

  Compounds of Formulas Ia and Ib, and stereoisomers, geometric isomers, tautomers, solvates, metabolites and pharmaceutically acceptable salts thereof, are useful for inhibiting receptor tyrosine kinases and for treating disorders mediated thereby. Methods of using compounds of Formula Ia and Ib, and stereoisomers, geometric isomers, tautomers, solvates and pharmaceutically acceptable salts thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed.

  式Ia和Ib化合物的复合物及其立体异构体、几何异构体、互变异构体、溶剂合物、代谢物和药学上可接受的盐，可用于抑制受体酪氨酸激酶并治疗由此介导的疾病。本发明公开了使用式Ia和Ib化合物的复合物及其立体异构体、几何异构体、互变异构体、溶剂合物和药学上可接受的盐，用于体外、原位和体内诊断、预防或治疗哺乳动物细胞中的此类疾病或相关的病理状况的方法。
• [EN] INHIBITING TRABID<br/>[FR] INHIBITION DE TRABID
  申请人：INTEGRAL EARLY DISCOVERY INC

  公开号：WO2020227168A1

  公开（公告）日：2020-11-12

  The present disclosure is directed to compounds of formulas (I) - (VII), which are useful as modulators of TRABID. The compounds are further useful in the inhibition of TRABID and the treatment of diseases or disorders associated with the inhibition of TRABID. For instance, the disclosure is concerned with compounds and compositions for inhibition of TRABID, methods of treating diseases associated with the inhibition of TRABID (e.g., autoimmune inflammatory diseases including, but not limited to, psoriasis), and methods of synthesis of these compounds.

  本公开涉及化合物的结构式(I) - (VII)，这些化合物可作为TRABID的调节剂。这些化合物进一步可用于抑制TRABID并治疗与TRABID抑制相关的疾病或紊乱。例如，本公开涉及用于抑制TRABID的化合物和组合物，治疗与TRABID抑制相关的疾病的方法（例如，包括但不限于自身免疫性炎症性疾病，如牛皮癣），以及这些化合物的合成方法。
• Sulfonyl amide inhibitors of calcium channel function
  申请人：Hangeland J. Jon

  公开号：US20050245535A1

  公开（公告）日：2005-11-03

  Compounds of formula I its stereoisomers, solvates, and salts, thereof, wherein: a, b, c, d, f, n, m and Ra are defined herein are are inhibitors of calcium channel function, and are useful in treating calcium channel-dependent disorders, including hypertension.

  化合物I的立体异构体、溶剂合物和盐类，其中：a、b、c、d、f、n、m和Ra的定义如下，是钙通道功能的抑制剂，并且在治疗依赖于钙通道的疾病，包括高血压方面具有用处。
• Novel peptides as NS3-serine protease inhibitors of hepatitis C virus
  申请人：——

  公开号：US20020068702A1

  公开（公告）日：2002-06-06

  The present invention discloses novel peptide compounds containing eleven amino acid residues which have HCV protease inhibitory activity as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such peptides as well as methods of using them to treat disorders associated with the HCV protease.

  本发明揭示了含有十一个氨基酸残基的新型肽化合物，具有HCV蛋白酶抑制活性，以及制备这些化合物的方法。在另一实施方案中，本发明还揭示了包含这些肽段的药物组合物，以及使用它们治疗与HCV蛋白酶相关的疾病的方法。
• QUINOLINE COMPOUNDS AND METHODS OF USE
  申请人：Gaudino John

  公开号：US20110053931A1

  公开（公告）日：2011-03-03

  Compounds of Formula (I), and stereoisomers, geometric isomers, tautomers, solvates, metabolites, salts and pharmaceutically acceptable prodrugs thereof, are useful for inhibiting receptor tyrosine kinases and for treating hyperproliferative disorders mediated thereby. Methods of using compounds of Formula (I), and stereoisomers, geometric isomers, tautomers, solvates and pharmaceutically acceptable salts thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed.

  式（I）的化合物及其立体异构体、几何异构体、互变异构体、溶剂化物、代谢物、盐和药学上可接受的前药，用于抑制受体酪氨酸激酶并治疗由此介导的过度增殖性疾病。本文揭示了使用式（I）的化合物及其立体异构体、几何异构体、互变异构体、溶剂化物和药学上可接受的盐，在哺乳动物细胞中进行体外、体内和原位诊断、预防或治疗此类疾病或相关病理条件的方法。